CClinicalTrials.gg
Not yet recruitingNCT07230574Updated Nov 17, 2025

Autologous Decidual-like Natural Killer Cells Therapy for Reproductive Failure

A Phase 2 interventional study of NK cell perfusion group in Abortion, Missed, Infertility Unexplained and Reproductive Disorder, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Not yet recruiting. Open to female participants aged 22 Years to 38 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
22 Years to 38 Years
Sex
Female
01

Study summary

The aim of this study is to verify the efficacy of in vitro induction of autologous decidual-like NK cells therapy for reproductive failure associated with uterine NK cells abnormalities.

Read the detailed description

Participants with reproductive failure and reproductive intentions will be recruited and screened. After obtaining their informed consent, menstrual blood analysis will be performed. Participants with menstrual blood NK cell abnormalities will be randomly assigned to either the NK cell perfusion group or control group in a ratio of 2:1. After completing two rounds of NK cell therapy, the NK cell perfusion group will enter the follow-up period, while the control group will not receive interventions after randomization and enter the follow-up period directly. The following information will be recorded for all participants who undergo menstrual blood NK cell analysis, including menstrual blood analysis results, attempts to conceive, and pregnancy outcomes during the follow-up period.

02

Conditions studied

  • Abortion, Missed
  • Infertility Unexplained
  • Reproductive Disorder

Browse trials for

Keywords

  • Recurrent Pregnancy Loss
  • Repeated Implantation Failure
  • Unexplained Infertility
  • Decidual Natural Killer Cells
03

Who can participate

Ages eligible
22 Years to 38 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Reproductive failure with abnormal endometrial natural killer (NK) cells in menstrual blood;
  • With a clear intention to conceive;
  • Normal ovarian function, or premature ovarian insufficiency with ≥2 high-quality cryopreserved embryos available for transfer;
  • Endometrial thickness measured by transvaginal ultrasound during the periovulatory period ≥7 mm;
  • Body mass index (BMI) between 18 kg/m² and 28 kg/m²;
  • Willing to comply with the follow-up plan of this study.

Exclusion criteria

Exclusion Criteria:

  • Use of progesterone receptor modulators;
  • One of the couple's chromosomal karyotype abnormalities, with no euploid embryo identified via preimplantation genetic testing for aneuploidy;
  • Severe endometriosis or adenomyosis, uterine fibroids affecting uterine cavity morphology, uterine malformations, intrauterine adhesions, or thin endometrium;
  • Uncontrolled autoimmune or endocrine disorders;
  • Contraindications to pregnancy;
  • History of malignant tumors;
  • Participating in other clinical studies;
  • Allergy to blood products.
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
159 participants (estimated)

Study arms

  • Experimental
    NK cell perfusion group

    Accepting NK cell therapy

    Biological: NK cell perfusion group

  • No intervention
    Control group

    Not accepting NK cell therapy

Interventions

  • BiologicalNK cell perfusion group

    Completing two rounds of NK cell therapy

05

What researchers measure

Primary outcomes

  1. Ongoing pregnancy rate

    Ongoing pregnancy is defined as at least 12 weeks of gestation, with ultrasound indicating fetal cardiac activity and fetal size consistent with the gestational age

    Time frame: 6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome

Secondary outcomes

  1. Improvement rate of NK cells

    Improvement rate of NK cells in menstrual blood analysis after intrauterine perfusion of autologous decidual-like NK cells

    Time frame: 6 months

  2. Clinical pregnancy rate

    Clinical pregnancy is defined as the presence of a gestational sac in the uterine cavity as indicated by ultrasound at 5-7 weeks of gestation

    Time frame: 6 months

  3. Miscarriage rate

    Miscarriage is defined as the pregnancy loss before 28 weeks of gestation

    Time frame: 6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome

  4. Preterm birth rate

    Preterm birth is defined as delivery at 28 to 37 weeks of gestation

    Time frame: 6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome

  5. Live birth rate

    Live birth is defined as delivery of any number of neonates born at 26 or more weeks' gestation with signs of life

    Time frame: 6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07230574
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators
The University of Science and Technology of China, Sir Run Run Shaw Hospital, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of University of Science and Technology of China
Responsible party
Yali Hu (M.D., Ph.D., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School) — Principal investigator
First posted
Nov 17, 2025
Start date
Nov 2025 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 17, 2025

Study contacts

Yali Hu
Contact
glyyhuyali@163.com
86-025-83106666 ext. 11201
Hui Zhu
Contact
zhuhui1231@126.com
86-025-8310666 ext. 54330
Yali Hu
principal investigator · The Affiliated Drum Tower Hospital of Nanjing University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion